Company news
NRX Pharmaceuticals, Inc. news in 2025
NRX Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100
June 30, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic
June 26, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
June 25, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)
June 22, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners
June 16, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
June 15, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 11, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network
June 6, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
June 5, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
June 4, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval
May 28, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition
May 27, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21
May 21, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
May 20, 2025
IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
May 20, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup
May 16, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement
May 15, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
May 14, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute
May 13, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ: NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
May 12, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025
May 11, 2025
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
May 6, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 5, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine
May 4, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
April 29, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 20, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
April 2, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
March 30, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
March 23, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 16, 2025
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025
March 11, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
February 5, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Engage BTIG as Financial Advisor
February 2, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt
January 27, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
January 27, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
January 20, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.
January 14, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
January 13, 2025
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market
January 12, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
January 9, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8...
January 6, 2025
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
January 5, 2025
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics
January 5, 2025
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025
January 2, 2025
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
January 1, 2025
Calls in 2025
- NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2025 Earnings Call
Nov 17, 2025
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2025 Earnings Call
Aug 20, 2025
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2025 Earnings Call
May 15, 2025
Transcript - NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2024 Earnings Call
Mar 17, 2025
Transcript
Decks in 2025
- Investor Presentation (October 2025)
Investor deck · 25 slides · October 2025